Cardiovascular events are the main cause of death in people receiving renal replacement therapy by programmed hemodialysis (HD). There is a constant increase in the number of patients receiving HD worldwide. This situation is associated with a steady increase in the number of cases of chronic kidney disease (CKD) and an increase in the number of patients with the terminal stage of the disease; the availability of HD for a wide range of patients, increasing the life expectancy of patients, changing most of the criteria for selecting patients for HD. The use of phosphate binders (PB) is one of the main methods of correcting mineral - bone disorders (MBD), and, in particular, hyperphosphatemia, which is considered today as a key factor in the development of CKD-MBD, cardiovascular complications and an increased risk of death in patients on dialysis. The use of a new calcium-free PB based on an iron - complex of iron oxyhydroxide, sucrose and starch provides a long-term high efficiency of hyperphosphatemia control with a simple and convenient dosing and administration regimen, which improves the quality of life of patients, increases adherence to treatment and significantly reduces the risk of developing adverse events, including fatal cardiovascular outcomes. Correction of hyperphosphatemia is a prerequisite for the successful management of this group of patients and influencing the prognosis.

Keywords: sucrose and starch (VELPHORO), complex of iron oxyhydroxide, mineral - bone disorders in chronic kidney disease, phosphate binders, hyperphosphatemia